24.47
0.27 (1.12%)
Penutupan Terdahulu | 24.20 |
Buka | 23.74 |
Jumlah Dagangan | 548,566 |
Purata Dagangan (3B) | 634,198 |
Modal Pasaran | 1,153,493,760 |
Harga / Pendapatan (P/E TTM) | 8.87 |
Harga / Jualan (P/S) | 1.62 |
Harga / Buku (P/B) | 1.45 |
Julat 52 Minggu | |
Tarikh Pendapatan | 5 Aug 2025 - 11 Aug 2025 |
Margin Keuntungan | 19.38% |
Margin Operasi (TTM) | 21.87% |
EPS Cair (TTM) | 2.76 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -0.80% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | -41.40% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 86.86% |
Nisbah Semasa (MRQ) | 2.95 |
Aliran Tunai Operasi (OCF TTM) | 193.17 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.71 M |
Pulangan Atas Aset (ROA TTM) | 7.60% |
Pulangan Atas Ekuiti (ROE TTM) | 19.90% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
Stok | Amphastar Pharmaceuticals, Inc. | Menaik | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 3.5 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | -0.5 |
Purata | 1.50 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. |
|
Sektor | Healthcare |
Industri | Drug Manufacturers - Specialty & Generic |
Gaya Pelaburan | Small Core |
% Dimiliki oleh Orang Dalam | 23.68% |
% Dimiliki oleh Institusi | 72.67% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 35.00 (Wells Fargo, 43.03%) | Beli |
Median | 32.50 (32.82%) | |
Rendah | 30.00 (JP Morgan, 22.60%) | Pegang |
Purata | 32.50 (32.82%) | |
Jumlah | 1 Beli, 1 Pegang | |
Harga Purata @ Panggilan | 24.50 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
JP Morgan | 12 May 2025 | 30.00 (22.60%) | Pegang | 24.34 |
Wells Fargo | 08 May 2025 | 35.00 (43.03%) | Beli | 24.65 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
22 May 2025 | Pengumuman | Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference |
09 May 2025 | Pengumuman | Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference |
07 May 2025 | Pengumuman | Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 |
30 Apr 2025 | Pengumuman | Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025 |
03 Apr 2025 | Pengumuman | Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |